It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. After-hours trades for Editas Medicine Inc. (EDIT) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by +$0.35, or +2.84%, to $12.68. Volume reached 28,929 shares, with price reaching a high of $12.69 and a low of $12. Recently, Yahoo Finance discussed the stock, revealing that Editas Medicine to Participate in Upcoming Investor Conferences.
Editas Medicine Inc. is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $12.53 and fluctuated between $12.72 as its day high and $11.72 as its day low. The current market capitalization of Editas Medicine Inc. is $855.55M. A total of 1.51 million shares were traded on the day, compared to an average of 1.66M shares.
Insider trades are also considered as indicators of how a stock will perform in the future, in addition to stock predictions. During the recent three months, EDIT has seen 1 BUY and 1 SELL insider trades, representing the acquisition of 58,372 and the disposition of 293 shares. Over the last 12 months, there were 10 BUYs and 14 SELLs from insiders. Insiders purchased 325,575 shares during that period but sold 46,771.
In the most recent transaction, ROBERTSON MICHELLE sold 192 shares of EDIT for 15.01 per share on Sep 06. After the transaction, the EVP, CHIEF FINANCIAL OFFICER now owns 82,475 company shares. In a previous transaction on Sep 06, Eaton Bruce sold 101 shares at 15.01 per share. EDIT shares that EVP, CHIEF BUSINESS OFFICER owns now total 65,027.
Among the insiders who sold shares, Eaton Bruce disposed of 293 shares on Aug 09 at a per-share price of $18.60. This resulted in the EVP, CHIEF BUSINESS OFFICER holding 65,128 shares of EDIT after the transaction. In another insider transaction, Shearman Mark S sold 5,145 shares at $10.06 per share on Jun 15. Company shares held by the EVP, CHIEF SCIENTIFIC OFFICER now total 68,349.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. According to analysts who have offered 12-month price targets for EDIT in the last 3 months, the mean price target is $30.00 with high estimates of $80.00 and low estimates of $8.00. In terms of 52-week highs and lows, EDIT has a high of $42.11 and a low of $9.59.
As of this writing, EDIT has an earnings estimate of $-0.89 per share for the current quarter. EPS was calculated based on a consensus of 8 estimates, with a high estimate of $-0.78 per share and a lower estimate of $-1.01. The company reported an EPS of $-0.78 in the last quarter, which was 7.14% higher than expectations of $-0.84.
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information.
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 18 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for EDIT is Underweight with a score of 3.17. A total of 6 analysts rated the stock as Buy while 1 rated it as Overweight while 8 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 3 thought it should be Sold.